main_header@2x

Increase Success in Drug Discovery While Reducing Time and Cost with RepliGut®

ABOUT US

Altis Biosystems has created a next-generation in vitro platform that reduces the time and cost of developing safer, more effective drugs.

By replicating native human biology, the intestinal stem cell platform produces more accurate and reproducible data for better clinical trial performance and reduces the need for animal testing.

home_img1_mob

PLATFORM

The RepliGut® Platform

RepliGut® is a unique, stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.

With a scalable platform, actionable data, high throughput screening to test thousands of compounds, and an unrivaled biobank, RepliGut® is the future of in vitro testing during drug development.

SERVICES

The RepliGut® is a reproducible and scalable platform that is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.

home_icon1

Intestinal Barrier Function

Maintains barrier integrity with high TEER values

Inflammatory Response

Inflammatory Response

Comprised of polarized intestinal cells grown on transwells

home_icon4

GI Toxicity

Screen compounds for 
drug-induced GI toxicity early

home_icon3

Intestinal Drug Disposition

Developed to replace Caco-2 cells (cancer cells) and animals

NEWS AND ARTICLES

August 8, 2022

Webinar: Gut-On-A-Chip - Assessing Drug-induced Gut Toxicity In Vitro

Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin, Ph.D, Chief Scientific Officer, Altis Biosystems discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.    

Watch Video

April 1, 2022

The Next Big Thing in Pharma

Bill Thelin, Ph.D, Chief Scientific Officer at Altis Biosystems discusses the future of healthcare, and what's the next big thing in pharma. Bill focuses on how the development of microphysiological systems will support the development of drugs from discovery to humans.    

Watch Video

DIGITAL EVENTS

CONTACT US

Have a question? Want to stay informed about Altis, RepliGut, and more platforms currently under development? Send us a message!